ClinicalTrials.gg
CompletedNCT04890145Updated Dec 3, 2024

The RW-Precision-Coupler Clinical Investigation

An interventional study of RW-Precision-Coupler in Hearing Loss, sponsored by MED-EL Elektromedizinische Geräte GesmbH. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by MED-EL Elektromedizinische Geräte GesmbH · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The RW-Precision-Coupler Clinical Investigation is prospective, non-randomized, open label, single subjects repeated measures, longitudinal monocentric trial. The primary aim of this pre-market clinical investigation is to evaluate the clinical performance and safety of VSB together with the VSB RWP-Coupler in the treatment of hearing loss. As secondary aims are to evaluate the clinical performance of VSB together with RWP-Coupler by measuring Sound Field audiometry (SF), to evaluate the safety of VSB together with RWP-Coupler by measuring bone conduction (BC) thresholds and collecting and assessing adverse events.

02

Conditions studied

  • Hearing Loss

Browse trials for

Keywords

  • Vibrant Soundbridge System
  • RW-Precision-Coupler
03

In context

Hearing Loss

1,109 studies on the registry are indexed under Hearing Loss; 233 are open to participants now.

This study's enrollment of 5 is below the median of 40 across 778 interventional studies indexed under Hearing Loss.

Browse Hearing Loss studies →

Lead sponsor

MED-EL Elektromedizinische Geräte GesmbH is the lead sponsor of 36 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Geographically and physically able to return to the investigational site for scheduled evaluations and follow-up appointments

    • Fluent in the German language
    • Persons of 18 years of age or older
    • Signed and dated informed consent before the start of any study-specific procedure
    • The physician must fully assess the potential risks and benefits for the patient prior to the decision to implant the RW-Precision-Coupler. The physician must exercise medical judgment and consider the patient's complete hospital record (also called medical history)
    • No previous active middle ear implant surgery performed in the implanted ear
    • The following indication for VORP503:

      • For a patient with sensorineural hearing loss, pure-tone air conduction threshold levels at or within the levels listed below:
      • For a patient with conductive or mixed hearing loss, pure tone bone-conduction threshold levels at or within the levels listed below:
      • A patient shall present with an ear anatomy that can facilitate positioning of the FMT in contact with a suitable vibratory structure of the ear.
      • A patient with sensorineural hearing loss shall be a current user of an acoustic hearing aid and have used this aid for at least 4 hours (average) per day for at least 3 months prior to evaluation, or shall not be able to wear or benefit from conventional hearing aids for medical reasons.
      • A patient shall be psychologically and emotionally stable with realistic expectations of the benefits and limitations of the Soundbridge

Exclusion criteria

Exclusion Criteria:

  • Simultaneous participation in another clinical trial (on device or on drug) which would interfere with the results of the study

    • Pregnancy or lactation
    • Contraindication for RWP-Coupler Sizer:

      • if a patient is known to be intolerant of the materials used in the RWP-Coupler.
      • if a patient is known to be intolerant of the materials used in the RWP-Coupler Sizer.
      • in case of a fixed stapes footplate.
    • Contraindication for VORP503:

      • A patient is known to be intolerant of the materials used in the implant (medical grade silicone elastomer, medical grade epoxy and titanium).
      • A patient with retrocochlear, or central auditory disorders.
      • A patient with nonresponsive active ear infection and/or chronic fluid in or about the ear.
      • A patient whose hearing loss has demonstrated an improving and decreasing fluctuation over a two-year period of 15 dB in either direction.
      • A patient with any physical, psychological, or emotional disorder that would interfere with surgery or the ability to perform on test and rehabilitation procedures.
      • A patient with a skin or scalp condition that may preclude attachment of the audio processor with a magnet.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Mild to severe hearing loss

    Device: RW-Precision-Coupler

Interventions

  • DeviceRW-Precision-Coupler

    Implantation of the RW-Precision-Coupler together with FMT-VORP 503

06

What researchers measure

Primary outcomes

  1. Freiburger Monosyllable Test

    Investigate the improvement of unaided pre-activation Word Recognition Scores (WRS) to 6 months post-operation aided WRS with RW-Precision-Coupler

    Time frame: 6 months post-operative

07

Study locations

1 site
  • Medical School Hannover
    Hanover, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04890145
Responsible party
Sponsor
First posted
May 18, 2021
Start date
May 19, 2021
Primary completion
Nov 26, 2024
Completion
Nov 26, 2024
Last update
Dec 3, 2024

Study contacts

Lenarz Thomas, Prof. h.c. Dr.
principal investigator · Medizinische Hochschule Hannover Klinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion